Meeting
2023 ASCO Genitourinary Cancers Symposium
Impact of run-in treatment with abiraterone acetate and prednisone (AAP) in the MAGNITUDE study of niraparib (NIRA) and AAP in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations.
Authors
Elena Castro
University Hospital Virgen de la Victoria (HUVV), Málaga, Spain
Elena Castro , Kim N. Chi , Shahneen Sandhu , David Olmos , Gerhardt Attard , Marniza Saad , Andrea Juliana Gomes , Dana E. Rathkopf , Matthew Raymond Smith , Taek Won Kang , Felipe Melo Cruz , Umberto Basso , Gary Mason , Adam del Corral , Shiva Dibaj , Daphne Wu , Brooke Diorio , Angela Mennicke Lopez- Gitlitz , Deniz Tural , Eric Jay Small
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT03748641
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr 172)
DOI
10.1200/JCO.2023.41.6_suppl.172
Abstract #
172
Poster Bd #
F9
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Gene-by-gene analysis in the MAGNITUDE study of niraparib (NIRA) with abiraterone acetate and prednisone (AAP) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and homologous recombination repair (HRR) gene alterations.
First Author: Shahneen Sandhu
First Author: Elena Castro
Poster
2024 ASCO Genitourinary Cancers Symposium
Real-world treatment patterns in patients with BRCA 1/2-positive (BRCA+) metastatic castration-resistant prostate cancer (mCRPC) initiating first-line (1L) therapy.
First Author: Mehmet Asim Bilen
First Author: Arun Azad